Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant T-VEC and Pembrolizumab for Stage III Melanoma
NCT03842943Phase 2Recruiting
- Sponsor
- University of Louisville
- Start
- Jul 2019
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors, Oncolytic Viruses, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talimogene laherparepvec and pembrolizumab in cutaneous melanoma (CM), sponsored by University of Louisville. Primary endpoint: Pathologic Complete Response at 6 months. Started Jul 2019; status: recruiting.
02
Drugs
talimogene laherparepvecpembrolizumab
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT03842943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03842943.